StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ — Southern California cord blood regenerative therapeutics company StemCyte is pleased…